Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2021

View Archived Issues

Novel series of 5,5-fused bicyclic PRMT5 inhibitors as potential anticancer therapeutics

Phase II results of suvratoxumab to prevent S. aureus ventilator-associated pneumonia

C4 selects CFT-8919 for progression into IND-enabling studies

The University of Pennsylvania describes fibronectin-targeting chimeric antigen receptors

AXL oncogene inhibitors discovered at Jiangsu Chia Tai Tianqing Pharmaceutical Group

Dual GLP-1/GCGR agonists synthesized at Dongguan Hec Biological Medicine Research & Development

Oncobix divulges mutant ALK/mutant EGFR inhibitors

REVOLUTION Medicines patents RAS inhibitors

Beclin-1 implicated in diabetic cardiomyopathy

FDA accepts IND application for LY-3819469

Oncorus announces development plans for its novel synthetic vRNA immunotherapy candidates

Gene signature governs anti-plaque microglia in AD

China NMPA approves CTA for phase IIb trial of AM-006 in Parkinson's disease

Activation of MT2 reduces cardiac I/R injury in prediabetic rats

Topical bevacizumab-800CW is safe for detecting esophageal lesions during NIR-FME

OSE's COVID-19 vaccine CoVepiT enters first-in-human study

DSMB recommends continuation of uniQure's phase I/II trial of AMT-130 in Huntington's disease

New biomarkers found to monitor disease progression in eosinophilic esophagitis

Preclinical data show AdCOVID neutralizes SARS-CoV-2 B.1.351 variant

Cystic Fibrosis Foundation awards support research at Metagenomi and Eloxx

AGT103-T HIV therapeutic enters first-in-human study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....